Drugs / MGD024
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05362773 | Jul 2022 → Nov 2026 expected | CD4+/CD56+ hematodermic neoplasm, acute myeloid leukemia, aggressive systemic mastocytosis, chronic myeloid leukemia +3 | MacroGenics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-11-02 | MacroGenics | Regulatory MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Results macrogenics.com ↗
Investigational New Drug (IND) application submitted for MGD024, a next generation DART ® molecule targeting CD123 and CD3 for AML |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-11-02 | MacroGenics | MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Results macrogenics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MGD024 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05362773 ↗ |
| Action | Deplete | “MGD024 is a CD123 x CD3 bispecific DART® molecule designed to target CD123-expressing leukemic cells for elimination by CD3-expressing T lymphocytes.” NCT05362773 ↗ |
| Modality | Protein / enzyme biologic | “MGD024 is a CD123 x CD3 bispecific DART® molecule designed to target CD123-expressing leukemic cells for elimination by CD3-expressing T lymphocytes.” NCT05362773 ↗ |